G
Ginny Gildengorin
Researcher at Children's Hospital Oakland Research Institute
Publications - 37
Citations - 1456
Ginny Gildengorin is an academic researcher from Children's Hospital Oakland Research Institute. The author has contributed to research in topics: Mechanical ventilation & Intensive care unit. The author has an hindex of 18, co-authored 37 publications receiving 1239 citations. Previous affiliations of Ginny Gildengorin include Children's Hospital Oakland.
Papers
More filters
Journal ArticleDOI
A prospective study of ventilator-associated pneumonia in children.
Ramya Srinivasan,Jeanette M. Asselin,Ginny Gildengorin,Jeanine P. Wiener-Kronish,Heidi R. Flori +4 more
TL;DR: In mechanically ventilated, critically ill children, those with ventilator-associated pneumonia had a prolonged need for mechanical ventilation, a longer ICU stay, and a higher mortality rate.
Journal ArticleDOI
Positive fluid balance is associated with higher mortality and prolonged mechanical ventilation in pediatric patients with acute lung injury.
TL;DR: Positive fluid balance was associated with a significant increase in both mortality and prolonged duration of mechanical ventilation, independent of the presence of multiple organ system failure and the extent of oxygenation defect.
Journal ArticleDOI
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.
Claudia R. Morris,Frans A. Kuypers,Lisa Lavrisha,Michael Ansari,Nancy Sweeters,Melinee Stewart,Ginny Gildengorin,Lynne Neumayr,Elliott Vichinsky +8 more
TL;DR: Arginine is a safe and inexpensive intervention with narcotic-sparing effects that may be a beneficial adjunct to standard therapy for sickle cell-related pain in children, and a large multi-center trial is warranted in order to confirm these observations.
Journal ArticleDOI
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Jean Y. Tang,Jean Y. Tang,Mina S. Ally,Mina S. Ally,Anita M. Chanana,Julian Mackay-Wiggan,Michelle Aszterbaum,Joselyn Lindgren,Grace Ulerio,Melika Rezaee,Ginny Gildengorin,Jackleen Marji,Charlotte Clark,David R. Bickers,Ervin H. Epstein +14 more
TL;DR: The interim analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial in patients with the basal-cell nevus (Gorlin) syndrome indicating that the smoothened inhibitor vismodegib reduces basal-cells carcinoma tumour burden and prevents new basal- cell carcinoma growth is reported.
Journal ArticleDOI
High Rates of O ’ Nyong Nyong and Chikungunya Virus Transmission in Coastal Kenya
A. Desiree LaBeaud,A. Desiree LaBeaud,Tamara Banda,Julie Brichard,Eric M. Muchiri,Peter Mungai,Francis M. Mutuku,Erin M. Borland,Ginny Gildengorin,Sarah Pfeil,Crystal Y. Teng,Kristin M. Long,Mark T. Heise,Ann M. Powers,Uriel Kitron,Charles H. King +15 more
TL;DR: Alphavirus exposure, particularly ONNV exposure, is common in coastal Kenya with ongoing interepidemic transmission of both Chikungunya virus and CHIKV, and household location may be a defining factor for the ecology of alphaviral transmission in this region.